(相关资料图)
智通财经APP获悉，周四，再鼎医药(ZLAB.US)美股股价拉涨，截至发稿，该股涨超45%，报49.48美元。公司旗下擎乐和纽再乐两款产品首度参与国家医保谈判。机构指，若进入医保目录，23年料进一步放量。
本周，德邦证券指出，新一轮国家医保谈判即将启动，大品种23年或将进入放量期。本次，再鼎医药旗下擎乐和纽再乐两款产品首度参与谈判。中信建投(601066)认为，若顺利进入医保目录，两个产品预计23年可以进一步放量。预计公司22年-24年，实现营收分别为13.70亿元、19.22亿元、31.24亿元。
2023-01-06
2023-01-06
2023-01-06
2023-01-06
2023-01-05
2023-01-05
2023-01-05
2023-01-04
2023-01-04
2023-01-04
2023-01-04
2023-01-04
2023-01-03
2023-01-03
2023-01-03
2023-01-03
2023-01-03
2023-01-03
2023-01-02
2023-01-02
2023-01-01
2023-01-01
2022-12-31
2022-12-30
2022-12-30
2022-12-30
2022-12-30
2022-12-29
2022-12-29
2022-12-29
2022-12-29
2022-12-29
2022-12-29
2022-12-28
2022-12-28
2022-12-28
2022-12-28
2022-12-28
2022-12-27
2022-12-27
2022-12-27
2022-12-26
2022-12-26
2022-12-26
2022-12-25
2022-12-25
2022-12-24
2022-12-23
2022-12-23
2022-12-23
2022-12-22
2022-12-22
2022-12-22
2022-12-21
2022-12-21
2022-12-21
2022-12-20
2022-12-20
2022-12-19
2022-12-19
2022-12-19
2022-12-19
2022-12-18
2022-12-17
2022-12-16
2022-12-16
2022-12-16
2022-12-15
2022-12-15
2022-12-15
2022-12-14
2022-12-14
2022-12-14
2022-12-13
2022-12-13
2022-12-12
2022-12-12
2022-12-10
2022-12-09
2022-12-08
2022-12-06
2022-08-07
2022-07-08
2022-05-20
2022-05-20
2022-03-20
2022-03-20
2022-03-20
2022-03-20
2022-03-20
2022-03-20
2022-03-20
2021-11-03
2021-11-03
2021-11-03
2021-11-03
2021-11-03
2021-11-03
2021-11-03
2021-11-03